Targeted degradation of Pin1 by an antagonistic peptide enhances gemcitabine therapy in pancreatic cancer

Mengting Chen, Xiangyu Chu, Haipeng Zhao, Lilusi Ma, Jie Meng, Yanlian Yang, Qiaojun Fang, Xiaocui Fang and Chen Wang

RSC Med. Chem., 2026, 17, 1537
DOI: 10.1039/D5MD00970G

Prospects and advances of PROTAC in the treatment of hematologic malignancies

Xinyang Wang, Ming Zhang and Heng Mei

Exp Hematol Oncol, 2026, 15
DOI: 10.1186/s40164-026-00759-3

Uncovering druggable hotspots on Pin1 via X-ray crystallographic fragment screening

Qingjie Xiao, Jianchao Tang, Huangliang Shu, Tingting Wu, Haijiao Zhang, Weihua Wang, Lei Wang and Wenming Qin

European Journal of Medicinal Chemistry, 2025, 299, 118048
DOI: 10.1016/j.ejmech.2025.118048

Structure-Guided Optimization and Preclinical Evaluation of 6-O-Benzylguanine-Based Pin1 Inhibitor for Hepatocellular Carcinoma Treatment

Wenchen Pu, Xianyan Shen, Xin Fan, Yuanyuan Zheng, Xuesha Liu, Jiao Li, Jian-Kang Zhou, Juan He, Rong Wei, Yanqiu Gong, Qingquan Zheng, Yao Luo, Yingli Guo, Min Ai, Yue Ming, Zixia Ye, Yun Zhao, Chun Wang and Yong Peng

J. Med. Chem., 2025, 68, 2869
DOI: 10.1021/acs.jmedchem.4c02144

The Role of Ubiquitination Regulation in Nasopharyngeal Carcinoma

Zhenyu Yan, Xiang Cao, Chengxian Ma, Yizhi Ge, Dan Zong and Xia He

Cancer Investigation, 2026, 44, 224
DOI: 10.1080/07357907.2025.2597501

ZC3H13 facilitates the progression of acute myeloid leukemia through m6A-FOXP1-mediated metabolic reprogramming

Jiaheng Wang, Linjuan Xu, Gang Wang, Wenping Wu and Hongwei Kong

Experimental Hematology, 2025, 151, 104862
DOI: 10.1016/j.exphem.2025.104862

Re-Evaluating PIN1 as a Therapeutic Target in Oncology Using Neutral Inhibitors and PROTACs

Chuan Liu, Zhonghui Chen, Tao Chen, Hongmei Song, Jianbo Shen, Xiaoxi Yuan, Shuai Xia, Qian Liu, Qiuxia Chen, Qiang Tian, Xiaoyun Meng, Zhu Han, Xiaofei Dong, Yu Yang, Longying Cai, Xuemin Cheng, Yangyang Jia, Guansai Liu, Jin Li, Junyou Ge and Dengfeng Dou

J. Med. Chem., 2024, 67, 15780
DOI: 10.1021/acs.jmedchem.4c01412

Pre-clinical evaluation of a potent and effective Pin1-degrading agent in pancreatic cancer

Giulia Alboreggia, Tiane Li, Anne Marie Prentiss, Parima Udompholkul, Frank Xia, Tim Synold, Jun Wu, Mingye Feng, Mustafa Raoof and Maurizio Pellecchia

Molecular Therapy Oncology, 2025, 33, 201078
DOI: 10.1016/j.omton.2025.201078

Discovery of Potent and Selective G9a Degraders for the Treatment of Pancreatic Cancer

Yunkai Shi, Qianqian Shen, Ruikai Long, Yiwen Mao, Shuaihang Tong, Yaxi Yang, Jing Gao, Hu Zhou, Yi Chen and Bing Zhou

J. Med. Chem., 2024, 67, 13271
DOI: 10.1021/acs.jmedchem.4c01192

Pin1: Advances in pancreatic cancer therapeutic potential and inhibitors research

Nan Wang, Tian Chai, Xing-Rong Wang, Yi-Dan Zheng, Chun-Yan Sang and Jun-Li Yang

Bioorganic Chemistry, 2024, 153, 107869
DOI: 10.1016/j.bioorg.2024.107869

Therapeutic innovations: targeting ROS production in AML with natural and synthetic compounds

Mohammed Hashim Mohammed, Raed Fanoukh Aboqader Al-Aouadi, Subasini Uthirapathy, Gaurav Sanghvi, Rekha M M, Resan Shakir Abdulamer, G. V. Siva Prasad, Mayank Kundlas, Fayzulla Khamraev and Muhammad Ikram Ullah

Naunyn-Schmiedeberg's Arch Pharmacol, 2025, 398, 11387
DOI: 10.1007/s00210-025-04054-6

Systematic Optimization of Proteolysis-Targeting Chimeras for PIN1 Enables Selective Degradation and Antitumor Activity In Vivo

Yuying Ma, Yang Teng, Jinjin Liu, Yuke Deng, Lingbo Xu, Ruichen Gao, Tingyu Peng, Wei Li, Yue Wei, Linfeng Li and Zufeng Guo

Pharmaceutics, 2026, 18, 288
DOI: 10.3390/pharmaceutics18030288

Targeted degradation of Pin1 by protein-destabilizing compounds

Giulia Alboreggia, Parima Udompholkul, Isaac Rodriguez, Gregor Blaha and Maurizio Pellecchia

Proc. Natl. Acad. Sci. U.S.A., 2024, 121
DOI: 10.1073/pnas.2403330121